Deka Bank Deutsche Girozentrale Neurocrine Biosciences Inc Transaction History

Deka Bank Deutsche Girozentrale

$51 Billion
Q1 2025

A detailed history of Deka Bank Deutsche Girozentrale transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 116,223 shares of NBIX stock, worth $15.4 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

116,223

Previous 115,973 0.22%

Holding current value

$15.4 Million

Previous $16 Million 19.19%

% of portfolio

0.03%

Previous 0.03%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 30, 2025	BUY	$107.22 - $153.29 $26,805 - $38,322	250 Added 0.22%	116,223 $12.9 Million
Q3 2024 Oct 24, 2024	BUY	$114.58 - $153.15 $273,502 - $365,569	2,387 Added 2.1%	115,973 $13.2 Million
Q2 2024 Aug 08, 2024	SELL	$130.86 - $143.19 $345,077 - $377,592	-2,637 Reduced 2.27%	113,586 $15.2 Million
Q1 2024 Apr 24, 2024	BUY	$130.4 - $143.74 $6.08 Million - $6.7 Million	46,627 Added 67.0%	116,223 $15.9 Million
Q4 2023 Jan 24, 2024	BUY	$106.07 - $132.76 $1.63 Million - $2.04 Million	15,367 Added 28.34%	69,596 $9.14 Million
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $183,809 - $228,930	1,955 Added 3.74%	54,229 $6.21 Million
Q2 2023 Jul 25, 2023	BUY	$89.53 - $104.87 $253,459 - $296,886	2,831 Added 5.73%	52,274 $4.92 Million
Q1 2023 Apr 24, 2023	SELL	$94.11 - $123.02 $12,422 - $16,238	-132 Reduced 0.27%	49,443 $4.88 Million
Q4 2022 Feb 01, 2023	BUY	$106.72 - $127.06 $53,466 - $63,657	501 Added 1.02%	49,575 $5.92 Million
Q3 2022 Nov 02, 2022	BUY	$92.03 - $107.81 $472,482 - $553,496	5,134 Added 11.68%	49,074 $4.99 Million
Q2 2022 Aug 03, 2022	SELL	$75.79 - $100.07 $6,593 - $8,706	-87 Reduced 0.2%	43,940 $4.28 Million
Q1 2022 Apr 28, 2022	BUY	$72.45 - $94.81 $92,156 - $120,598	1,272 Added 2.98%	44,027 $4.2 Million
Q4 2021 Feb 02, 2022	BUY	$79.65 - $106.22 $610,915 - $814,707	7,670 Added 21.86%	42,755 $3.58 Million
Q3 2021 Oct 22, 2021	SELL	$86.18 - $99.03 $61,877 - $71,103	-718 Reduced 2.01%	35,085 $3.31 Million
Q2 2021 Aug 05, 2021	BUY	$89.43 - $102.27 $61,170 - $69,952	684 Added 1.95%	35,803 $3.45 Million
Q1 2021 Apr 28, 2021	BUY	$87.57 - $119.4 $505,103 - $688,699	5,768 Added 19.65%	35,119 $3.33 Million
Q4 2020 Mar 12, 2021	SELL	$86.91 - $108.33 $126,627 - $157,836	-1,457 Reduced 4.73%	29,351 $2.74 Million
Q3 2020 Oct 29, 2020	BUY	$96.16 - $135.15 $2.34 Million - $3.29 Million	24,370 Added 378.53%	30,808 $2.97 Million
Q2 2020 Aug 04, 2020	BUY	$85.09 - $130.36 $174,434 - $267,238	2,050 Added 46.72%	6,438 $803,000
Q1 2020 May 14, 2020	SELL	$75.11 - $113.76 $175,006 - $265,060	-2,330 Reduced 34.68%	4,388 $399,000
Q4 2019 Feb 04, 2020	SELL	$86.8 - $118.57 $1.88 Million - $2.56 Million	-21,613 Reduced 76.29%	6,718 $739,000
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $6.61 Million - $8.01 Million	-78,880 Reduced 73.57%	28,331 $2.56 Million
Q2 2019 Aug 01, 2019	BUY	$72.24 - $91.27 $2.54 Million - $3.21 Million	35,131 Added 48.74%	107,211 $8.83 Million
Q1 2019 May 10, 2019	BUY	$69.31 - $91.53 $661,910 - $874,111	9,550 Added 15.27%	72,080 $8.8 Million
Q4 2018 Feb 12, 2019	SELL	$68.32 - $124.36 $652,455 - $1.19 Million	-9,550 Reduced 13.25%	62,530 $4.42 Million
Q3 2018 Nov 09, 2018	SELL	$98.88 - $125.85 $150,297 - $191,292	-1,520 Reduced 2.07%	72,080 $0
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $2.26 Million - $3.18 Million	30,000 Added 68.81%	73,600 $7.16 Million
Q1 2018 May 03, 2018	SELL	$75.88 - $92.43 $5.23 Million - $6.37 Million	-68,900 Reduced 61.24%	43,600 $3.61 Million
Q3 2017 Nov 06, 2017	BUY	$47.97 - $61.28 $5.4 Million - $6.89 Million	112,500	112,500 $6.02 Million

Others Institutions Holding NBIX

# of Institutions

648

Shares Held

96.9M

Call Options Held

749K

Put Options Held

553K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.7B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.

Account

Deka Bank Deutsche Girozentrale Neurocrine Biosciences Inc Transaction History